Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
作者信息
O'Brien Thomas R, Thomas David L, Jackson Sarah S, Prokunina-Olsson Ludmila, Donnelly Raymond P, Hartmann Rune
机构信息
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
Abstract
摘要
相似文献
1
Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
2
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
3
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00985-20.
4
Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Front Immunol. 2020 May 28;11:1229. doi: 10.3389/fimmu.2020.01229. eCollection 2020.
5
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
6
Interplay between SARS-CoV-2 and the type I interferon response.
PLoS Pathog. 2020 Jul 29;16(7):e1008737. doi: 10.1371/journal.ppat.1008737. eCollection 2020 Jul.
7
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Cell Host Microbe. 2020 Jun 10;27(6):870-878. doi: 10.1016/j.chom.2020.05.008. Epub 2020 May 27.
8
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.
Lancet Respir Med. 2020 Jul;8(7):687-695. doi: 10.1016/S2213-2600(20)30193-4. Epub 2020 May 7.
9
Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
Eur J Immunol. 2020 Jul;50(7):932-938. doi: 10.1002/eji.202048693. Epub 2020 Jun 15.
10
More questions than answers, and a way ahead.
G Ital Nefrol. 2020 Apr 9;37(2):2020-vol2.
引用本文的文献
1
Targeting CTP synthetase 1 to restore interferon induction and impede nucleotide synthesis in SARS-CoV-2 infection.
mBio. 2025 Apr 29:e0064925. doi: 10.1128/mbio.00649-25.
2
COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes.
Commun Biol. 2023 Dec 13;6(1):1265. doi: 10.1038/s42003-023-05626-z.
3
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2.
Nat Commun. 2023 Dec 12;14(1):8229. doi: 10.1038/s41467-023-43447-0.
4
Association of Interferon Lambda 3 and 4 Gene SNPs and Their Expression with COVID-19 Disease Severity: A Cross-Sectional Study.
Infect Drug Resist. 2023 Oct 10;16:6619-6628. doi: 10.2147/IDR.S422095. eCollection 2023.
5
Viral recognition and the antiviral interferon response.
EMBO J. 2023 Jul 17;42(14):e112907. doi: 10.15252/embj.2022112907. Epub 2023 Jun 27.
6
IFNλ: balancing the light and dark side in pulmonary infection.
mBio. 2023 Aug 31;14(4):e0285022. doi: 10.1128/mbio.02850-22. Epub 2023 Jun 6.
7
Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV.
Vaccines (Basel). 2023 Feb 18;11(2):480. doi: 10.3390/vaccines11020480.
8
Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study.
Virol J. 2022 Dec 15;19(1):218. doi: 10.1186/s12985-022-01944-6.
9
Phase separation in immune regulation and immune-related diseases.
J Mol Med (Berl). 2022 Oct;100(10):1427-1440. doi: 10.1007/s00109-022-02253-9. Epub 2022 Sep 9.
10
Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries.
Nat Biomed Eng. 2022 Aug;6(8):992-1003. doi: 10.1038/s41551-022-00925-y. Epub 2022 Aug 19.
本文引用的文献
1
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
2
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
3
HBV/HDV Coinfection: A Challenge for Therapeutics.
Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24.
4
Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis.
Rev Med Virol. 2018 May;28(3):e1977. doi: 10.1002/rmv.1977. Epub 2018 Apr 17.
5
IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission.
Elife. 2018 Apr 13;7:e33354. doi: 10.7554/eLife.33354.
6
Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness.
Immunity. 2017 May 16;46(5):875-890.e6. doi: 10.1016/j.immuni.2017.04.025.
7
IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.
EMBO Mol Med. 2016 Sep 1;8(9):1099-112. doi: 10.15252/emmm.201606413. Print 2016 Sep.
8
SARS and MERS: recent insights into emerging coronaviruses.
Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27.
9
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24.
10
Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia.
PLoS Pathog. 2013;9(11):e1003773. doi: 10.1371/journal.ppat.1003773. Epub 2013 Nov 21.
Zotero 插件